Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $9.55 Analyst target: $29.50 Upside: 208.90%
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.
See the full interactive analysis & chart →Informational only — not investment advice.